

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s): Dean Engelhardt et al.  
Serial No.: 08/486,069  
Filed: June 7, 1995  
For: NUCLEIC ACID SEQUENCING PROCESSES  
USING NON-RADIOACTIVE MODIFIED OR LABELED  
NUCLEOTIDES OR NUCLEOTIDE ANALOGS, AND  
OTHER PROCESSES FOR NUCLEIC ACID DETECTION  
AND CHROMOSOMAL CHARACTERIZATION USING  
SUCH NON-RADIOACTIVE DETECTABLE MODIFIED  
OR LABELED NUCLEOTIDES OR NUCLEOTIDE  
ANALOGS (AS PREVIOUSLY AMENDED)

Group Art Unit: 1631  
Ex'r: Ardin H. Marschel, Ph.D.

#58/W  
Plunkett  
(NE)  
response to  
non-comp. And,  
needed first

527 Madison Avenue (9<sup>th</sup> Floor)  
New York, New York 10022  
March 12, 2001


**FILED BY EXPRESS MAIL**

Honorable Commissioner of Patents and Trademarks  
Washington, D.C. 20231

**COMMUNICATION FOR TRANSMITTING SECOND COMPOSITE CLAIM SET**  
**(FOLLOWING APPLICANTS' MARCH 9, 2001**  
**AMENDMENT UNDER 37 C.F.R. §1.115)**

Dear Sirs:

This Communication follows Applicants' March 9, 2001 Amendment Under 37 C.F.R. §1.115 which was in response to the January 30, 2001 Office Action issued in connection with the above-identified application. Because the purpose of this Communication is to transmit a composite claim set, which submission is within the three month period set forth in the January 30, 2001 Office Action, no extension request or fee is believed due in connection with this Communication.

EXPRESS MAIL CERTIFICATE	
"Express Mail" Label No.	EL839968874US
Deposit Date	March 12, 2001
I hereby certify that this paper and the attachments herein are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington DC 20231.	
 Ronald C. Fedus Reg. No. 32,567	MAR 12 2001 Date

Dean L. Engelhardt, II.

Serial No.: 08/486,069

Filed: June 7, 1995

Page 3 [Communication For Transmitting Second Composite Claim Set (Following Applicants' March 9, 2001 Amendment Under 37 C.F.R. §1.115 (In Response To The January 30, 2001 Office Action)) - March 12, 2001]


### SUMMARY AND CONCLUSIONS

Claims 569-717, 719-869, 871-1021, 1023-1173, 1175-1294, 1296-1407, 1409-1568, 1570-1612 and 1614-1727 continue to be presented for further examination in this application. No changes to the claims have been effected by this Communication.

No fee or fees are believed to be due in connection with this Communication. In the event that any other fee or fees are due, however, authorization is hereby given to charge the amount of any such fee(s) to Deposit Account No. 05-1135, or to credit any overpayment thereto.

If a telephone conversation would further the prosecution of the present application, Applicants' undersigned attorney request that he be contacted at the number provided below.

Respectfully submitted,



Ronald C. Fedus  
Registration No. 32,567  
Attorney for Applicants

ENZO DIAGNOSTICS, INC.  
c/o ENZO BIOCHEM, INC.  
527 Madison Avenue, 9<sup>th</sup> Floor  
New York, New York 10022  
Telephone: (212) 583-0100  
Facsimile: (212) 583-0150

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Engelhardt et al.  
 Serial No. 08/486,069  
 Filed: June 7, 1995  
 Type: **NP**  
 Group Art Unit: 1631  
 Examiner: Ardin H. Marschel, Ph.D.  
**NUCLEIC ACID SEQUENCING PROCESSES USING NON-RADIOACTIVE MODIFIED OR LABELED NUCLEOTIDES OR NUCLEOTIDE ANALOGS, AND OTHER PROCESSES FOR NUCLEIC ACID DETECTION AND CHROMOSOMAL CHARACTERIZATION USING SUCH NON-RADIOACTIVE MODIFIED NUCLEOTIDES OR NUCLEOTIDE ANALOGS (As Previously Amended)**

**FILED BY EXPRESS MAIL**

Honorable Commissioner of  
 Patents and Trademarks  
 Washington, D. C. 20231

Sir:

Transmitted herewith is a Communication For Transmitting Second Composite Claim Set (Following Applicants' March 9, 2001 Amendment Under 37 C.F.R. §1.115) in the above-identified patent application.

The fee has been calculated as shown below:

	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE	ADDITIONAL FEE
Total	1619	Minus	1619	= 0	X \$ 18	\$ 0
Indep	24	Minus	24	= 0	X \$ 80	\$ 0
( )	First Presentation of Multiple Dependent Claims				+\$270	\$ 0
	TOTAL ADDITIONAL FEE					\$ 0


- ( ) Charge Deposit Account No. 05-1135 in the amount of \$ \_\_\_\_\_.
- ( ) A check in the amount of \$ \_\_\_\_\_ is attached.
- (X) The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 05-1135: any filing fees under 37 C.F.R. §1.16 for the presentation of extra claims and any patent application processing fees under 37 C.F.R. §1.17.

Copies are being provided in triplicate.


Also enclosed: \_\_\_\_\_

March 12, 2001  
 Date

Respectfully submitted,

  
 Ronald C. Fedus  
 Registration No. 32,567  
 Attorney for Applicant(s)

ENZO DIAGNOSTICS, INC.  
 c/o Enzo Biochem, Inc.  
 527 Madison Avenue (9<sup>th</sup> Fl.)  
 New York, New York 10022  
 Tel. (212) 583-0100  
 Attorney's Docket No.: Enz-5(D8)(C2)

EXPRESS MAIL CERTIFICATE	
"Express Mail" Label No.	EL839968874US
Deposit Date	March 12, 2001
I hereby certify that this paper and the attachments herein are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington DC 20231.	
 Ronald C. Fedus Reg. No. 32,567	MAR 12 2001 Date

Enz-5(D8)(C2)